within Pharmacolibrary.Drugs.ATC.J;

model J01DC09
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.02666666666666667,
    adminDuration  = 600,
    adminMass      = 1.0,
    adminCount     = 1,
    Vd             = 0.0002,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Cefmetazole is a second-generation cephamycin antibiotic used for the treatment of infections caused by susceptible Gram-positive and Gram-negative bacteria. It is used primarily in Japan and some Asian countries for respiratory, urinary, and intra-abdominal infections, but is not widely approved in the US or EU.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult volunteers after single intravenous administration.</p><h4>References</h4><ol><li>J J Schentag,Cefmetazole sodium: pharmacology, pharmacokinetics, and clinical trials.,Pharmacotherapy,1991<a href='https://pubmed.ncbi.nlm.nih.gov/2020609/'>https://pubmed.ncbi.nlm.nih.gov/2020609/</a></li><li>Yuki Kaiki, Hiroki Ohge, Kazuro Ikawa, Shinnosuke Uegami, Yusuke Watadani, Norifumi Shigemoto, Toshinori Hirano, Kosuke Yoshimura, Hiroki Kitagawa, Norifumi Morikawa, Shinya Takahashi,Pharmacokinetics of cefmetazole in plasma, peritoneal fluid, peritoneum, and subcutaneous adipose tissue of patients scheduled for lower gastrointestinal surgery: Dosing considerations based on site-specific pharmacodynamic target attainment.,Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy,2023<a href='https://pubmed.ncbi.nlm.nih.gov/36549644/'>https://pubmed.ncbi.nlm.nih.gov/36549644/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end J01DC09;
